Cheryl Boss
Adult Health · Orland Park, ILNPI 1760436109
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,916 of the $5,635 with a category attached, or 87.3%. 15 manufacturers reported payments, led by Novo Nordisk at 38.2% of the total. Reporting peaked in 2021 at $1,624 and has fallen 50.6% since, to $802 in 2025. Among adult health clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 335 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$675
- AstraZeneca$431
- Sanofi-aventis U.S. LLC$417
- Abbott$213
- plus $698 from 9 others
What the payments were for
- Food & beverage$4,91687%
- Education$71813%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 122 | $2,150 |
| Lilly USA, LLC | 74 | $1,052 |
| Boehringer Ingelheim | 38 | $675 |
| AstraZeneca | 25 | $431 |
| Sanofi-aventis U.S. LLC | 28 | $417 |
| Abbott | 14 | $213 |
| Dexcom, Inc. | 9 | $212 |
| Mannkind Corporation | 3 | $105 |
| Insulet Corporation | 6 | $103 |
| Bayer | 4 | $100 |
| Tandem Diabetes Care, Inc. | 7 | $82 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Ascensia Diabetes Care US Inc. | 1 | $29 |
| Medtronic | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,635 in reported general payments places this provider in the 90th percentile of 553 adult health providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 231 | $392,954 |
| JardianceEmpagliflozin | 124 | $172,457 |
| MounjaroTirzepatide | 76 | $105,882 |
| Humalog Kwikpen U-200Insulin Lispro | 69 | $91,578 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 84 | $85,395 |
| FarxigaDapagliflozin Propanediol | 61 | $75,470 |
| TrulicityDulaglutide | 50 | $72,362 |
| Tresiba Flextouch U-200Insulin Degludec | 59 | $68,000 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $40,466 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 20 | $39,120 |
| Tresiba Flextouch U-100Insulin Degludec | 60 | $34,420 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 26 | $29,362 |
| Novolog FlexpenInsulin Aspart | 83 | $18,348 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $17,692 |
| FiaspInsulin Aspart (Niacinamide) | 12 | $13,720 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $2,150 | $413,785258 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $675 | $190,149136 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,052 | $183,667155 claims |
| AstraZenecaFarxiga | $431 | $75,47061 claims |
| Sanofi-aventis U.S. LLCLantus | $417 | $1,45813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 553 adult health providers in Illinois.
Other adult health in Orland Park
- Kimberly KearnsHoffman Estates$531K
- Leslie ForresterArlington Heights$97K
- Colleen FolkersChicago$86K
- Matthew BurkeChicago$44K
- Jacklyn GideonChicago$38K
- Jennifer GreenfieldChicago$35K
- Tammy PomaChicago$32K
- Tammy BrownNorth Chicago$31K
- Eileen SchedelAurora$21K
- Julia BuesserGurnee$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.